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constraints of heart dosimetry (V45<50%, V60<30%, heart mean dose<20Gy) predict late damage; do not predict AP. Therefore
it could be considered a side-effect non-dose-dependent.
Conclusions. AP is a rare complication of BC radiotherapy treatment and its diagnosis is clinical. Because it can occur with very
low doses, it should be considered in the differential diagnosis of all chest pain episodes in BC patients undergoing radiotherapy,
regardless the dose administered at its onset.
http://dx.doi.org/10.1016/j.rpor.2013.03.105
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Introduction. Radiotherapy is the standard treatment after breast conserving surgery (BCS) in early-stage breast cancer. There is
evidence that an additional boost in tumor bed decreases the risk of local recurrence. However, there is not an ideal method
of radiation delivering. New technologies have improved accuracy on irradiation of malignancies in order to not injure normal
tissues (i.e. IGRT) Non-invasive breast brachitherapy (NIBB), AccuBoost, is our new system at ICO.
Purpose. Implementation of NIBB since April 2012. We have started a Phase II trial to evaluate the feasibility, toxicity and local
control of AccuBoost in patients with early-stage breast cancer.
Materials and methods. AccuBoost system applies breast brachytherapy without invasive catheters, and with mammographic
image guidance using stereotactic localization for tumor bed boost. AcuuBoost applicators are selected by radiation oncologist
who delimitates tumor bed (PTV) by mammography before each fraction delivery. From July 2012 to January 2013 we performed
56 treatments with AccuBoost.
Results. All patients underwent BCS before receiving RDT. Boost (16Gy) was delivered while WBRT (50Gy) administered. Repro-
ducibility of the tumor bed by mammography to be covered by AccuBoost applicators and good tolerance to compression in CC
and ML orientations were required. Tumor bed identiﬁcation required intraoperative clip placements to be deﬁned and also using
either seromas or postoperative changes. The mean CC and ML breast compressions were 5.1 and 6.1 cm, respectively. 35% of the
sessions were delivered using 6.0 round shape applicator. 27% were performed with 5.0 round shape and 5.3 D shape applicator.
Conclusion. NIBB is a unique and precise method of delivering HDR-photon irradiation to the tumor-bed tissue using mammo-
graphic image-guidance before each boost fraction delivery. AccuBoost allows a major optimization of external radiation units
and proﬁtability of HDR.
http://dx.doi.org/10.1016/j.rpor.2013.03.106
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Introduction. Skin is involved in most of radiotherapy (RT) treatments, however, systems to determinate the radiation-induced
skin toxicity are usually based on visual subjective rating scales. Radiation causes a vascular skin response which increases
as skin affectation increases. This response can be measured in order to obtain an objective assessment of radiation-induced
toxicity.
Objective. To establish a measurement system that allows us to quantify skin toxicity produced by RT.
Materials and methods. A laser Doppler ﬂowmeter (LDF), Periﬂux PF 3, has been used to measure in real time the cutaneous
microcirculation. 1824 measurements (912 in the irradiated area and 912 in the not irradiated area) have been performed aiming
to evaluate the cutaneous reaction over the irradiated skin area from patients of different pathologies undergoing RT. A baseline
measure for every measured point is taken before starting the RT treatment. Furthermore, to be able to observe the changes in
the microcirculation of the irradiated area with the delivered dose, several sets of measurements are taken at the same points
along the treatment and for one month after completing the RT treatment. At the same time, we performed a clinical assessment
of skin toxicity with the visual rating scale commonly used in RT.
Results. From the analysis of averaged measurements it can be observed a signiﬁcant increase of vascularization in the irradiated
area which increases with the administered dose. However, the measurements in the non-irradiated areas do not show a sig-
niﬁcant increase of vascularization. The measurements made once the treatment has ﬁnished show that microvascularization
decreases, tending to the baseline values.
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Conclusions. FLD is anobjective tool that asses radiodermatitis. This toolmayproveuseful for the reductionof radiationmorbidities
and improvement of patient quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.107
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Introduction. Radiation recall dermatitis (RRD) was ﬁrst described by D’Angio in 1959. Its frequency is not known, because most of
the reports are case reports. The interval between the end of RT and RRD ranges from days to years. Anthracyclines, alkylating
agents, antimetabolites, nucleoside analogs, taxanes, tamoxifen, simvastatin, anti-tuberculosis drugs, and exposure to ultraviolet
light, have been associated.
Objective. To assess the frequency and severity of RRD in BCP.
Materials and methods. 350 consecutive BCP undergoing radiotherapy (RT) were enrolled. All patients received supportive skin
treatment before, during and 4 weeks after RT. Follow-up ended 1 year after RT. Dermatitis (D) development during RT was
evaluated by the RTOG/EORTC criteria. RRD was evaluated by the speciﬁc NCI grading system developed in 2000, documented in
the 2.0 Common Toxicity Criteria.
Results. 253 patients presented D during RT. 75 patients had skin toxicity grade II or more. The mean dose of D appearance was
38.8Gy (range 30–42). At 5 months, skin appearance was good in all cases. Later, 19 patients presented RRD (15 GI, and 4 GII). All
these patients had received chemotherapy after RT. All cases improved rapidly with topical steroids.
Conclusions. As far as we know, this is the ﬁrst observational study assessing the frequency and severity of RRD. Idiosyncratic
drug hypersensitivity phenomenon is a recent hypothesis which correlates best with the present available facts. Certain drugs
trigger non-immune inﬂammatory pathways in patients whose inﬂammatory response threshold has been lowered by radiation.
Radiation may induce cells to secrete low levels of cytokines, such as TNF, that are responsible for an inﬂammatory response,
and when a triggering agent is introduced, these cytokines are upregulated, causing a recall reaction. Often, the recall reaction
is more severe than the original radiation reaction, which has not occurred in the patients we studied. Study continues.
http://dx.doi.org/10.1016/j.rpor.2013.03.108
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Introduction. In radiation-induced-cancer development are implicated low range radiation doses (up to 20–30Gy) received by the
healthy tissue, except for secondary sarcoma induced at higher doses.
Objective. To analyze the effects of 10–16Gy boost given [as second cancers potential-inducer in homolateral (HL) and contralateral
lung (CL) and breast (CB)], and ascertain if there is any difference if delivered by photons (PH) or electrons (E). We present the
preliminary results.
Materials and methods. 5 consecutive BCP, treated with conservative intend, undergoing RT, were enrolled. Eclipse v10.0 was used
for planning and DVH analysis. Statistical analysis was performed by MATLAB software. For each patient, two boost options were
calculated; one by PH and another by E. DVH of each were analyzed and determined: (a) V5-20Gy of HL and CL. (b) V5-10Gy of
CB. (c) V10-20Gy of esophagus. Also, the mean integral dose in the treated breast (MIDB) and the mean integral dose received in
the whole simulation volume (MIDWSV) were determined.
Results. Wilcoxon–Mann–Whitney test showed that the null hypothesis was true (median equal for both data samples, with a
signiﬁcance level of 5%) for HL, but false for MIDB and MIDWSV. Therefore, no signiﬁcant differences were found in HL between
both boost (PH or E), but they were found for MIDB (increased for E) and for MIDWSV (increased for PH).
Conclusions. There is a signiﬁcant difference between E or PH boost regarding low doses in distant organs. No differences were
found regarding lung doses. E boost possibly is more related to higher probability of homolateral induced breast sarcoma. Integral
dose (linked to general cancer induction) is also higher in PH boost. This low dose distribution might be used as optimization
criteria for a certain patient regarding election between E or PH boost with similar CTV coverage.
http://dx.doi.org/10.1016/j.rpor.2013.03.109
